Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

8 results about "Acid sphingomyelinase" patented technology

Acid sphingomyelinase is one of the enzymes that make up the sphingomyelinase (SMase) family, responsible for catalyzing the breakdown of sphingomyelin to ceramide and phosphorylcholine. They are organized into alkaline, neutral, and acidic SMase depending on the pH in which their enzymatic activity is optimal. Acid Sphingomyelinases (aSMases) enzymatic activity can be influenced by lipids, cations, pH, redox and other proteins in the environment. Specifically aSMases have been shown to have increased enzymatic activity in lysobisphophatidic acid (LBPA) or phosphatidylinositol (PI) enriched environments, and inhibited activity when phosphorylated derivatives of PI are present.

Dose-escalating enzyme replacement therapy for the treatment of acid sphingomyelinase deficiency

PendingRU2025100059AAcid sphingomyelinaseSubstitution therapy
Owner:MAUNT SINAJ SKUL OF MEDSIN +1

Use of amitriptyline in acid sphingomyelinase deficiency, Gaucher disease, globoid cell leukodystrophy and Niemann-Pick type C

ActiveCN120617224BAmitriptylineDisease
The present application provides the application of amitriptyline in the treatment of acid sphingomyelinase deficiency, Gaucher disease, globoid cell leukodystrophy and Niemann Pick type C.
Owner:XIN HUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

Marker for acid sphingomyelinase disorders and uses thereof

ActiveUS12589138B2Peptide/protein ingredientsHydrolasesBiochemistryAcid sphingomyelinase
The present disclosure provides methods of screening, diagnosing, monitoring and / or treating acid sphingomyelinase (ASM) disorders such as Niemann-Pick disease. In particular, the methods encompass techniques for improved diagnosis and / or treatment of an ASM disorder, for example using enzyme replacement therapy.
Owner:GENZYME CORP

Antibody specifically binding to ASM protein

PendingAU2022279876B2AntigenDisease
The present invention relates to an antibody specifically binding to an acid sphingomyelinase (ASM) protein. Particularly, the antibody or an antigen-binding fragment thereof, according to the present invention, specifically binds to the ASM protein, with high binding affinity, and, thus, can be effectively used for detecting the ASM protein or diagnosing, etc. a disease occurring due to overexpression of the ASM protein.
Owner:ISU ABXIS

Pharmaceutical compositions for treating acid sphingomyelinase deficiency

This invention provides a composition for treating acid sphingomyelinase deficiency (ASMD). [Solution] A composition comprising recombinant human acid sphingomyelinase, sodium phosphate, methionine, and sucrose is provided. A method for using the composition to treat patients with acid sphingomyelinase deficiency is also provided.
Owner:GENZYME CORP

ANTIBODIES THAT BIND SPECIFICALLY TO AN ASM PROTEIN

ActiveMA63510B1AntigenDisease
The present invention relates to an antibody specifically binding to an acid sphingomyelinase (ASM) protein. Particularly, the antibody or an antigen-binding fragment thereof, according to the present invention, specifically binds to the ASM protein, with high binding affinity, and, thus, can be effectively used for detecting the ASM protein or diagnosing, etc. a disease occurring due to overexpression of the ASM protein.
Owner:ISU ABXIS